Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTI-004: Eftilagimod Alfa + Pembrolizumab + Chemotherapy in Advanced/Metastatic NSCLC
NCT06726265Phase 3Active, not recruiting
- Sponsor
- Immutep Limited
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 27
01
Overview
A Phase 3 trial of eftilagimod alpha in non-small cell lung cancer (NSCLC), sponsored by Immutep Limited. Started Mar 2025; status: active, not recruiting.
02
Drugs
eftilagimod alpha
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06726265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06726265.